Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
ID: 357002Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357002

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-311.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer inflammation through innovative molecular imaging techniques. This initiative encourages applications that leverage in vivo imaging methods to provide deeper insights into the dynamic interactions between inflammation and cancer, moving beyond traditional in vitro approaches. The program seeks multidisciplinary collaborations among cancer biologists and imaging scientists to develop integrated imaging strategies and molecular probes for real-time monitoring of inflammatory responses within the tumor microenvironment. Interested applicants can apply for up to $500,000 annually for a maximum of five years, with the application deadline set for January 8, 2028. For further details, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-311.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-311-Full-Announcement.html
    PAR-24-311.html
    The National Cancer Institute (NCI) is issuing a funding opportunity through the R01 Research Project Grant mechanism to advance molecular imaging techniques in cancer inflammation research. Targeting innovations that leverage in vivo imaging, this initiative aims to provide deeper insights into the interplay between inflammation and cancer biology, moving beyond traditional in vitro methods which have limitations in capturing dynamic processes. Applications are encouraged to involve multidisciplinary collaborations among cancer biologists and imaging scientists, aspiring to develop molecular imaging probes and integrated approaches for real-time monitoring of inflammatory responses in the tumor microenvironment. Key eligibility requirements include the necessity for teams to comprise multiple Principal Investigators and the combination of various research methodologies, such as multi-omics and advanced imaging technologies. The program will accept applications until January 8, 2028, with up to $500,000 available annually for a maximum of five years for validated projects. This funding opportunity underscores the NCI's commitment to fostering cooperative, cross-disciplinary research for enhanced cancer treatment strategies.
    Similar Opportunities
    Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for R01 grant applications focused on the integration of imaging and fluid-based tumor monitoring in cancer therapy. The objective is to enhance research designs that utilize imaging and liquid biopsy assays to assess treatment responses and the emergence of resistance in cancer patients, thereby advancing precision medicine in cancer treatment. This initiative is critical for improving diagnostic techniques and patient monitoring strategies across various cancer types. Eligible applicants, including universities, for-profit organizations, and nonprofits, can apply for grants with a maximum budget of $500,000 per year for projects lasting up to five years. Applications will be accepted from January 5, 2025, until January 8, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems," aimed at fostering collaborations between academic and industrial entities to enhance imaging technologies for cancer-related challenges. This initiative encourages innovative proposals that detail mechanisms for clinical relevance and operational feasibility, with a focus on advancing the development and validation of imaging systems that can improve cancer detection, diagnosis, and treatment. Funding is available for projects with budgets capped at $500,000 per year for up to five years, and applications must involve at least one academic and one industrial investigator. Interested applicants should submit their proposals electronically by January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems," aimed at fostering collaborations between academic institutions and industrial organizations to enhance imaging technologies for cancer diagnosis and treatment. This initiative seeks to translate scientific discoveries and engineering advancements into practical tools that address significant challenges in cancer research, focusing on the development and validation of imaging systems that improve detection and treatment monitoring. The grant offers a maximum budget of $500,000 per year for up to five years, with applications required to include at least one academic and one industrial investigator. Interested applicants can find more information and submit their proposals by the deadline of January 7, 2027, by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), is offering a funding opportunity titled "Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis" under the R01 Research Project Grant program. This initiative aims to support research projects that implement early phase clinical trials (Phases 0, I, and II) focused on cancer-targeted diagnostic and therapeutic interventions, aligning with the NCI's mission to advance cancer research. Eligible applicants include a diverse range of organizations such as colleges, nonprofits, and governmental entities, with a maximum project budget of $499,999 in direct costs per year and an award period not exceeding five years. Interested parties should note that applications are due by January 7, 2027, and can seek further information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-081.html.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" grant, aimed at enhancing research into the relationship between co-infections and cancer. This initiative encourages exploratory studies that investigate how concurrent or sequential infections by multiple pathogens influence carcinogenesis, with a focus on mechanistic and epidemiological insights rather than clinical trials. The grant supports research that may inform cancer prevention and treatment strategies, particularly concerning infection-related cancers, with a maximum award of $275,000 for a two-year project period. Applications are due starting January 16, 2025, and interested applicants can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-083.html.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant titled "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This funding opportunity aims to support exploratory research projects that focus on the development and validation of innovative technologies designed to enhance the understanding of cancer biology, improve early detection, and address cancer health disparities. The program is part of the Innovative Molecular Analysis Technologies (IMAT) initiative and is particularly interested in projects that have overcome major feasibility gaps, as evidenced by preliminary data, but still require further validation for broader adoption in the research community. The total estimated funding for this program is $4.5 million, with individual awards ranging from $50,000 to $150,000, and a total of nine awards expected. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information. The application deadline is April 10, 2026, with awards anticipated to be made by December 1, 2026.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at supporting advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. This initiative encourages innovative projects that utilize nanoparticle formulations or nano-devices to address significant clinical objectives in cancer treatment, with a focus on enhancing treatment efficacy through combination therapies and immunotherapy. Funding is available up to $475,000 annually for a maximum of four years, with applications accepted from eligible institutions including higher education entities, nonprofits, and government organizations. Interested applicants should refer to the detailed application process outlined on Grants.gov and the NIH ASSIST system, with key deadlines spanning from April 2025 to November 2027. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.